Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Ensemble Results of PIM1 PIM PIM Ensemble Results of GSK3 GSK GSK GSK
Advertisements

Molecular Therapy - Nucleic Acids
Oligonucleotide Delivery to the Lung: Waiting to Inhale
Maik Goette, Martin C. Stumpe, Ralf Ficner, Helmut Grubmüller 
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Molecular Therapy - Nucleic Acids
Olivier Fisette, Stéphane Gagné, Patrick Lagüe  Biophysical Journal 
Targeting HSP70 for Cancer Therapy
Structure of an LDLR-RAP Complex Reveals a General Mode for Ligand Recognition by Lipoprotein Receptors  Carl Fisher, Natalia Beglova, Stephen C. Blacklow 
Molecular Therapy - Nucleic Acids
Takuo Osawa, Hideko Inanaga, Chikara Sato, Tomoyuki Numata 
AnchorDock: Blind and Flexible Anchor-Driven Peptide Docking
Volume 6, Issue 6, Pages (December 2000)
Opioid Receptor Three-Dimensional Structures from Distance Geometry Calculations with Hydrogen Bonding Constraints  Irina D. Pogozheva, Andrei L. Lomize,
Volume 14, Issue 5, Pages (May 2007)
Hydration and DNA Recognition by Homeodomains
Ubiquitin Recognition by the Human TSG101 Protein
Large-Scale Conformational Dynamics of the HIV-1 Integrase Core Domain and Its Catalytic Loop Mutants  Matthew C. Lee, Jinxia Deng, James M. Briggs, Yong.
Volume 108, Issue 1, Pages (January 2015)
Jan Hoinka, Phuong Dao, Teresa M Przytycka 
Molecular Therapy - Nucleic Acids
Volume 20, Issue 6, Pages (December 2005)
Molecular Recognition of CXCR4 by a Dual Tropic HIV-1 gp120 V3 Loop
Volume 4, Issue 5, Pages (November 1999)
Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis  Marcin Nowotny, Sergei A. Gaidamakov, Robert.
IRNA-PseColl: Identifying the Occurrence Sites of Different RNA Modifications by Incorporating Collective Effects of Nucleotides into PseKNC  Pengmian.
Volume 26, Issue 3, Pages (May 2007)
“DFG-Flip” in the Insulin Receptor Kinase Is Facilitated by a Helical Intermediate State of the Activation Loop  Harish Vashisth, Luca Maragliano, Cameron F.
Crystal Structure of Recombinant Human Interleukin-22
Molecular Therapy - Nucleic Acids
Ligand Binding to the Voltage-Gated Kv1
Volume 89, Issue 4, Pages (October 2005)
New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization  Abdullah Ozer, John M Pagano,
Volume 14, Issue 5, Pages (May 2006)
Molecular Therapy - Nucleic Acids
Functional Plasticity in the Substrate Binding Site of β-Secretase
Erratum The American Journal of Human Genetics
Karunesh Arora, Tamar Schlick  Biophysical Journal 
Wei-Yun Lai, Bo-Tsang Huang, Jen-Wei Wang, Pei-Ying Lin, Pan-Chyr Yang 
Molecular Therapy - Nucleic Acids
Replica Exchange Molecular Dynamics Simulations Provide Insight into Substrate Recognition by Small Heat Shock Proteins  Sunita Patel, Elizabeth Vierling,
What Does It Take to Bind CAR?
Volume 77, Issue 1, Pages (July 1999)
Hisashi Ishida, Steven Hayward  Biophysical Journal 
Volume 4, Issue 5, Pages (May 1996)
Min Wang, Mary Prorok, Francis J. Castellino  Biophysical Journal 
Volume 52, Issue 3, Pages (November 2013)
Volume 83, Issue 6, Pages (December 2002)
iRNA-PseU: Identifying RNA pseudouridine sites
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Molecular Therapy - Nucleic Acids
Volume 103, Issue 10, Pages (November 2012)
Structures of the Toll-like Receptor Family and Its Ligand Complexes
Molecular Therapy - Nucleic Acids
Conformational Transitions in Protein-Protein Association: Binding of Fasciculin-2 to Acetylcholinesterase  Jennifer M. Bui, Zoran Radic, Palmer Taylor,
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Volume 11, Issue 1, Pages 1-12 (April 2015)
Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis  Marcin Nowotny, Sergei A. Gaidamakov, Robert.
Molecular Therapy - Nucleic Acids
OmpT: Molecular Dynamics Simulations of an Outer Membrane Enzyme
Two Pathways Mediate Interdomain Allosteric Regulation in Pin1
Gydo C.P. van Zundert, Adrien S.J. Melquiond, Alexandre M.J.J. Bonvin 
Thomas J Cradick, Peng Qiu, Ciaran M Lee, Eli J Fine, Gang Bao 
Volume 84, Issue 4, Pages (April 2003)
Insights from Free-Energy Calculations: Protein Conformational Equilibrium, Driving Forces, and Ligand-Binding Modes  Yu-ming M. Huang, Wei Chen, Michael J.
Structural Basis for Ligand Binding to the Guanidine-I Riboswitch
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
CD28 Aptamers as Powerful Immune Response Modulators
Yogesh K. Gupta, Deepak T. Nair, Robin P. Wharton, Aneel K. Aggarwal 
Volume 16, Issue 3, Pages (March 2002)
Presentation transcript:

Molecular Therapy - Nucleic Acids In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study'TIM3 Aptamers Binding  Obdulia Rabal, Fernando Pastor, Helena Villanueva, Mario M Soldevilla, Sandra Hervas-Stubbs, Julen Oyarzabal  Molecular Therapy - Nucleic Acids  Volume 5, (January 2016) DOI: 10.1038/mtna.2016.84 Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Predicted binding mode for the 3D modelled structures of two study cases. (a) Docking of the 29-nt modeled RNA aptamer to NF-κB. (b) Docking of the 38-nt modeled RNA aptamer to 30S ribosomal protein S8. In both cases, green structure corresponds to the crystal structure, pink to the lowest RMSD in the most populated cluster (RMSD of 8.5 Å for 29-nt/NF-κB and 3.9 Å for 38-nt/30 S ribosomal), blue to the lowest scoring structure within the most populated cluster (RMSD of 20.7 Å for 29-nt/NF-κB and 13.0 Å for 38-nt/30 S ribosomal) and salmon to the most stable structure from all the 3,000 poses (RMSD of 28.6 Å and 42.9 Å for a and b, respectively). nt, nucleotide; RMSD, root mean square deviation. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.84) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Predicted binding mode of TIM3 aptamers. (a) Predicted binding of TIM3-Apt1 and TIM3-Apt2 to TIM3 showing the two possible binding modes: binding site 1 (TIM3-Apt1 in turquoise, TIM3-Apt2 in orange) with residues important for TIM3 ligand binding depicted (Arg112, Asp121 and Arg69), and binding site 2 (TIM3-Apt1 in blue and TIM3-Apt2 in green) with Lys86 and Lys99 in stick. The constant priming sequence is displayed in thin ribbon view. (b,c) Surface view of the selected predicted complex TIM3-Apt1 – TIM3 (b) and TIM3-Apt2 – TIM3 (c). Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.84) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Predicted binding mode of the TIM3 aptamers to TIM3 (pink ribbon) for the lowest DECK-RP scoring pose within the most populated cluster. Priming sequences of the aptamers are depicted in thin ribbon view and the variable 25-nt sequence in thick ribbon. For each aptamer, the TIM3 residues involved in hydrogen bond or ionic interactions, listed in Table 5, are shown. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.84) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions